Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
Crossref DOI link: https://doi.org/10.1186/s12974-017-0945-z
Published Online: 2017-08-31
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ziemssen, Tjalf
Tumani, Hayrettin
Sehr, Tony
Thomas, Katja
Paul, Friedemann
Richter, Nils
Samara, Emil
Spiegelstein, Ofer
Sorani, Ella
Bar-Ilan, Oren
Mimrod, Dorit
Hayardeny, Liat
Funding for this research was provided by:
Teva Pharmaceutical Industries